The Europe Endoscopic Retrograde Cholangiopancreatography Market is expected to witness market growth of 8.4% CAGR during the forecast period (2022-2028).
The surge in government initiatives, as well as a quick increase in awareness of endoscopic retrograde cholangiopancreatography devices and their availability, allows key Market players to invest in these devices.
Moreover, an increase in diagnostic imaging-related research activities along with improved research and development for advanced and safe endoscopic retrograde cholangiopancreatography (ECRP) has enhanced the productivity of the endoscopic retrograde cholangiopancreatography (ERCP) devices Market.
Endoscopic Retrograde Cholangiopancreatography (ERCP) procedure that uses endoscopy and x-rays to diagnose and treat bile and pancreatic duct problems. Precut sphincterotomy during endoscopic retrograde cholangiopancreatography (ERCP) may enhance the odds of cannulation success.
Due to the presence of prominent Market players supplying technically advanced ERCP devices and high healthcare expenditure levels across Germany, France, Italy, and the United Kingdom, the region held a significant share of the endoscopic retrograde cholangiopancreatography devices Market and is expected to remain dominant throughout the forecasting period.
Due to low therapeutic penetration in Europe, the Market is expected to increase significantly. High-growth countries such as the United Kingdom, France, and Germany is expected to contribute to the expansion of the European Market. Due to the lesser penetration of the Market, where revenue growth has not reached its full potential and future growth prospects, the rest of the Market for exocrine pancreatic insufficiency therapies is expected to rise at a faster rate than the other important regions.
The Germany Market dominated the Europe Endoscopic Retrograde Cholangiopancreatography Market by Country in 2021, and is expected to continue to be a dominant Market till 2028; thereby, achieving a Market value of $144.7 million by 2028. The UK Market is anticipated to grow at a CAGR of 7.5% during (2022-2028). Additionally, The France Market is expected to showcase a CAGR of 9.2% during (2022-2028).
Based on Procedure, the Market is segmented into Biliary Sphincterotomy, Biliary Stenting, Biliary Dialatation, Pancreatic Sphincterotomy, and Pancreatic Duct Stenting & Dilation. Based on Product, the Market is segmented into Endotherapy Devices, Endoscopes, Visualization Systems, Energy Devices, and Others. Based on Endotherapy Devices Type, the Market is segmented into Stents & Sphincterotomes, Catheters, Lithotripter, Cannulas, Forceps, Snares, Guiding Wires, Balloons, and Others. Based on End user, the Market is segmented into Hospitals, Ambulatory Surgery Centres & Clinics, and Others. Based on countries, the Market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The Market research report covers the analysis of key stakeholders of the Market. Key companies profiled in the report include Olympus Corporation, Fujifilm Holdings Corporation, Ambu A/S, Boston Scientific Corporation, Steris PLC, Johnson & Johnson, B. Braun Melsungen AG, ConMed Corporation, Medtronic PLC, and Karl Storz SE & Co. KG.
By Procedure
By Country
The surge in government initiatives, as well as a quick increase in awareness of endoscopic retrograde cholangiopancreatography devices and their availability, allows key Market players to invest in these devices.
Moreover, an increase in diagnostic imaging-related research activities along with improved research and development for advanced and safe endoscopic retrograde cholangiopancreatography (ECRP) has enhanced the productivity of the endoscopic retrograde cholangiopancreatography (ERCP) devices Market.
Endoscopic Retrograde Cholangiopancreatography (ERCP) procedure that uses endoscopy and x-rays to diagnose and treat bile and pancreatic duct problems. Precut sphincterotomy during endoscopic retrograde cholangiopancreatography (ERCP) may enhance the odds of cannulation success.
Due to the presence of prominent Market players supplying technically advanced ERCP devices and high healthcare expenditure levels across Germany, France, Italy, and the United Kingdom, the region held a significant share of the endoscopic retrograde cholangiopancreatography devices Market and is expected to remain dominant throughout the forecasting period.
Due to low therapeutic penetration in Europe, the Market is expected to increase significantly. High-growth countries such as the United Kingdom, France, and Germany is expected to contribute to the expansion of the European Market. Due to the lesser penetration of the Market, where revenue growth has not reached its full potential and future growth prospects, the rest of the Market for exocrine pancreatic insufficiency therapies is expected to rise at a faster rate than the other important regions.
The Germany Market dominated the Europe Endoscopic Retrograde Cholangiopancreatography Market by Country in 2021, and is expected to continue to be a dominant Market till 2028; thereby, achieving a Market value of $144.7 million by 2028. The UK Market is anticipated to grow at a CAGR of 7.5% during (2022-2028). Additionally, The France Market is expected to showcase a CAGR of 9.2% during (2022-2028).
Based on Procedure, the Market is segmented into Biliary Sphincterotomy, Biliary Stenting, Biliary Dialatation, Pancreatic Sphincterotomy, and Pancreatic Duct Stenting & Dilation. Based on Product, the Market is segmented into Endotherapy Devices, Endoscopes, Visualization Systems, Energy Devices, and Others. Based on Endotherapy Devices Type, the Market is segmented into Stents & Sphincterotomes, Catheters, Lithotripter, Cannulas, Forceps, Snares, Guiding Wires, Balloons, and Others. Based on End user, the Market is segmented into Hospitals, Ambulatory Surgery Centres & Clinics, and Others. Based on countries, the Market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The Market research report covers the analysis of key stakeholders of the Market. Key companies profiled in the report include Olympus Corporation, Fujifilm Holdings Corporation, Ambu A/S, Boston Scientific Corporation, Steris PLC, Johnson & Johnson, B. Braun Melsungen AG, ConMed Corporation, Medtronic PLC, and Karl Storz SE & Co. KG.
Scope of the Study
Market Segments Covered in the Report:
By Procedure
- Biliary Sphincterotomy
- Biliary Stenting
- Biliary Dialatation
- Pancreatic Sphincterotomy
- Pancreatic Duct Stenting & Dilation
- Endotherapy Devices
- Stents & Sphincterotomes
- Catheters
- Lithotripter
- Cannulas
- Forceps
- Snares
- Guiding Wires
- Balloons
- Others
- Endoscopes
- Visualization Systems
- Energy Devices
- Others
- Hospitals
- Ambulatory Surgery Centres & Clinics
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Olympus Corporation
- Fujifilm Holdings Corporation
- Ambu A/S
- Boston Scientific Corporation
- Steris PLC
- Johnson & Johnson
- Braun Melsungen AG
- ConMed Corporation
- Medtronic PLC
- Karl Storz SE & Co. KG
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. Europe Endoscopic Retrograde Cholangiopancreatography Market by Procedure
Chapter 5. Europe Endoscopic Retrograde Cholangiopancreatography Market by Product
Chapter 6. Europe Endoscopic Retrograde Cholangiopancreatography Market by End User
Chapter 7. Europe Endoscopic Retrograde Cholangiopancreatography Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Olympus Corporation
- Fujifilm Holdings Corporation
- Ambu A/S
- Boston Scientific Corporation
- Steris PLC
- Johnson & Johnson
- B. Braun Melsungen AG
- ConMed Corporation
- Medtronic PLC
- Karl Storz SE & Co. KG
Methodology
LOADING...
